title: Preoperative downstaging chemoradiation with concurrent irinotecan and capecitabine in MRI-defined locally advanced rectal cancer: a phase I trial (NWCOG-2).
abstract: BACKGROUND
  The aim of this study was to investigate the safety of neoadjuvant chemoradiation using radiotherapy (RT) combined with concurrent capecitabine and irinotecan for locally advanced rectal cancer before surgery.
  
  
  METHODS
  Forty-six patients were recruited and treated on the basis that MRI scanning had shown poor-risk tumours with threatening (< or =1 mm) or involvement of the mesorectal fascia. Conformal RT was given using 3 or 4 fields at daily fractions of 1.8 Gy on 5 days per week to a total dose of 45 Gy. Concurrently oral capecitabine was given twice daily throughout radiotherapy continuously from days 1 to 35 and intravenous irinotecan was given once per week during weeks 1 to 4 of RT. Dose levels were gradually escalated as follows. Dose level 1: capecitabine 650 mg m(-2) b.i.d. and irinotecan 50 mg m(-2); Dose level 2: capecitabine 650 mg m(-2) b.i.d. and irinotecan 60 mg m(-2); Dose level 3: capecitabine 825 mg m(-2) b.i.d. and irinotecan 60 mg m(2); Dose level 4: capecitabine 825 mg m(-2) b.i.d. and irinotecan 70 mg m(-2).
  
  
  RESULTS
  Diarrhoea (grade 3, no grade 4) was the main serious acute toxicity with lesser degrees of fatigue, neutropenia, anorexia and palmar-plantar erythrodysesthesia. The recommended dose for future study was dose level 2 at which 3 of 14 patients (21%) developed grade 3 diarrhoea. Postoperative complications included seven pelvic or wound infections and two anastomotic and two perineal wound dehiscences. There were no deaths in the first 30 days postoperatively. Of 41 resected specimens, 11 (27%) showed a pathological complete response (pCR) and five (12%) showed an involved circumferential resection margin (defined as < or =1 mm). The 3-year disease-free survival (intent-to-treat) was 53.2%.
  
  
  CONCLUSIONS
  In patients with poor-risk MRI-defined locally advanced rectal cancer threatening or involving the mesorectal fascia, preoperative chemoradiation based on RT at 45 Gy in 25 daily fractions over 5 weeks with continuous daily oral capecitabine at 650 mg m(-2) b.i.d. days 1-35 and weekly IV irinotecan at 60 mg m(-2) weeks 1-4, provides acceptable acute toxicity and postoperative morbidity with encouraging response and curative resection rates.
authors.affiliation: Department of Clinical Oncology, North Wales Cancer Treatment Centre, Rhyl LL18 5UJ, UK. simon.gollins@cd-tr.wales.nhs.uk
authors.forename: S W
authors.initials: SW
authors.lastname: Gollins
authors.forename: S
authors.initials: S
authors.lastname: Myint
authors.forename: S
authors.initials: S
authors.lastname: Susnerwala
authors.forename: B
authors.initials: B
authors.lastname: Haylock
authors.forename: M
authors.initials: M
authors.lastname: Wise
authors.forename: C
authors.initials: C
authors.lastname: Topham
authors.forename: L
authors.initials: L
authors.lastname: Samuel
authors.forename: R
authors.initials: R
authors.lastname: Swindell
authors.forename: J
authors.initials: J
authors.lastname: Morris
authors.forename: L
authors.initials: L
authors.lastname: Mason
authors.forename: E
authors.initials: E
authors.lastname: Levine
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D000069287:Capecitabine; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D006801:Humans; D000077146:Irinotecan; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D012004:Rectal Neoplasms / Q000473:pathology / Q000628:therapy*
chemical_list: D003841:Deoxycytidine; D000069287:Capecitabine; D000077146:Irinotecan; D005472:Fluorouracil; D002166:Camptothecin
references.citation: N Engl J Med. 2004 Oct 21;351(17):1731-40
references.pmid: 15496622
references.citation: J Clin Oncol. 2006 Feb 1;24(4):650-5
references.pmid: 16446336
references.citation: J Clin Oncol. 2005 Mar 1;23(7):1350-7
references.pmid: 15684318
references.citation: Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1311-20
references.pmid: 12654443
references.citation: Br J Cancer. 2008 Apr 8;98(7):1210-6
references.pmid: 18349840
references.citation: Dis Colon Rectum. 2002 Jul;45(7):857-66
references.pmid: 12130870
references.citation: Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):745-52
references.pmid: 16199310
references.citation: N Engl J Med. 2006 Sep 14;355(11):1114-23
references.pmid: 16971718
references.citation: Dis Colon Rectum. 1998 Aug;41(8):979-83
references.pmid: 9715152
references.citation: Br J Cancer. 2005 Apr 11;92(7):1215-20
references.pmid: 15785742
references.citation: Lancet. 1986 Nov 1;2(8514):996-9
references.pmid: 2430152
references.citation: Radiother Oncol. 2007 Dec;85(3):379-84
references.pmid: 18036687
references.citation: Clin Cancer Res. 1999 Oct;5(10):2948-53
references.pmid: 10537364
references.citation: Int J Radiat Oncol Biol Phys. 2003 Jan 1;55(1):132-7
references.pmid: 12504045
references.citation: Cancer Res. 1997 Apr 15;57(8):1529-36
references.pmid: 9108456
references.citation: BMJ. 2006 Oct 14;333(7572):779
references.pmid: 16984925
references.citation: Lancet. 2001 Oct 20;358(9290):1291-304
references.pmid: 11684209
references.citation: Br J Cancer. 2006 Apr 10;94(7):976-81
references.pmid: 16552435
references.citation: J Clin Oncol. 2008 Jan 10;26(2):303-12
references.pmid: 18182672
references.citation: Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):201-5
references.pmid: 16814947
references.citation: Lancet. 2009 Mar 7;373(9666):821-8
references.pmid: 19269520
references.citation: Ann Oncol. 2006 Mar;17(3):361-71
references.pmid: 16500912
references.citation: Br J Cancer. 2007 Feb 26;96(4):551-8
references.pmid: 17262086
references.citation: Br J Cancer. 2007 Mar 26;96(6):912-7
references.pmid: 17325705
references.citation: Lancet. 1993 Feb 20;341(8843):457-60
references.pmid: 8094488
references.citation: J Clin Oncol. 2006 Oct 1;24(28):4620-5
references.pmid: 17008704
references.citation: N Engl J Med. 2001 Aug 30;345(9):638-46
references.pmid: 11547717
references.citation: Ann Surg. 2002 Apr;235(4):449-57
references.pmid: 11923599
references.citation: Am J Surg Pathol. 2002 Mar;26(3):350-7
references.pmid: 11859207